1. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs)

   • Violetta Dymicka-Piekarska
   • Olga M. Koper-Lenkiewicz
   • Joanna Kamińska

   Review Open access 03 November 2020 Pages: 1497 - 1510

   

2. Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature

   • Fausto Meriggi
   • Alberto Zaniboni

   Review 09 November 2020 Pages: 1511 - 1517

3. Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma

   • O. Jimenez
   • S. Colli
   • P. Chabay

   Original Article 12 November 2020 Pages: 1519 - 1526

   

4. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review

   • Zhe Zhao
   • Xinfeng Wang
   • Dan Zhang

   Original Article 16 November 2020 Pages: 1527 - 1540

   

5. microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy

   • Gilli Galore-Haskel
   • Eyal Greenberg
   • Gal Markel

   Original Article 17 November 2020 Pages: 1541 - 1555

   

6. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma

   • Nuchjira Takheaw
   • Gunya Sittithumcharee
   • Seiji Okada

   Original Article 19 November 2020 Pages: 1557 - 1567

   

7. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo

   • G. de Jong
   • L. Bartels
   • K. Wagner

   Original Article 23 November 2020 Pages: 1569 - 1581

   

8. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

   • Vincenzo Di Noia
   • Ettore D’Argento
   • Emilio Bria

   Original Article Open access 24 November 2020 Pages: 1583 - 1592

   

9. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab

   • Nalee Kim
   • Jeong Il Yu
   • Kyunga Kim

   Original Article 24 November 2020 Pages: 1593 - 1603

   

10. Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

    • Changhee Park
    • Kyeonghun Jeong
    • Dae Seog Heo

    Original Article 24 November 2020 Pages: 1605 - 1617

    

11. Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10

    • Boxing Su
    • Haibo Han
    • Liqun Zhou

    Original Article 25 November 2020 Pages: 1619 - 1634

    

12. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes

    • Lukas Peiffer
    • Farnoush Farahpour
    • Jürgen C. Becker

    Original Article Open access 04 December 2020 Pages: 1635 - 1647

    

13. Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer

    • He Zhang
    • Guohui Qin
    • Sha Zhu

    Original Article Open access 10 December 2020 Pages: 1649 - 1665

    

14. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC

    • Marzia Del Re
    • Federico Cucchiara
    • Romano Danesi

    Original Article Open access 14 December 2020 Pages: 1667 - 1678

    

15. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations

    • Barbara Willvonseder
    • Fabian Stögbauer
    • Melanie Boxberg

    Original Article Open access 19 December 2020 Pages: 1679 - 1689

    

16. Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

    • Carlos Zamora
    • Mariona Riudavets
    • Silvia Vidal

    Original Article 02 January 2021 Pages: 1691 - 1704

    

17. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma

    • Ming Yi
    • Anping Li
    • Kongming Wu

    Original Article Open access 02 January 2021 Pages: 1705 - 1719

    

18. Immuno-PET imaging of ⁶⁸Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers

    • Qingzhu Liu
    • Lei Jiang
    • Ling Qiu

    Original Article 02 January 2021 Pages: 1721 - 1733

    

19. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer

    • Gisela María Suárez
    • Ana Laura Añé-Kourí
    • Agustin Lage

    Original Article 02 January 2021 Pages: 1735 - 1743

    

20. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors

    • Shinkichi Takamori
    • Kazuki Takada
    • Masaki Mori

    Original Article 03 January 2021 Pages: 1745 - 1753

    

21. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues

    • Shin Hye Yoo
    • Jihui Yun
    • Dae Seog Heo

    Original Article 03 January 2021 Pages: 1755 - 1769

    

22. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    • Mario Presti
    • Marie Christine Wulff Westergaard
    • Marco Donia

    Research Report 09 November 2020 Pages: 1771 - 1776

    

23. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

    • Fausto Petrelli
    • Alessandro Inno
    • Melissa Bersanelli

    Research Report 10 November 2020 Pages: 1777 - 1780

    

24. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

    • Simon Fietz
    • Romina Zarbl
    • Dimo Dietrich

    Research Report Open access 16 November 2020 Pages: 1781 - 1788

    

25. Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy

    • Qingsheng Li
    • Phuong T. Ngo
    • Nejat K. Egilmez

    Research Report 27 November 2020 Pages: 1789 - 1796